ArticlePloS one2026
A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnimal models have limited ability to predict human metabolically dysfunction-associated steatohepatitis (MASH), creating a major obstacle in drug development. To address this challenge, we introduce an integrated drug discovery approach that combines rational small-interfering RNA (siRNA) design and chemical modifications to improve stability, validated in a complex human 3D NAC-organoid MASH model.
methodsUsing this system, we created new GalNAc-conjugated siRNAs targeting the 17β-hydroxysteroid dehydrogenase 13 (HSD17B13). The lead candidates were evaluated for stability in human serum and liver microsomes, off-target risks, and efficacy in the 3D organoid model that mimics key disease features such as steatosis and fibrosis.
resultsOur main candidate, si-R5-42, demonstrated greater stability in human serum and liver microsomes, as well as fewer off-target risks. Most importantly, in the 3D organoid model, si-R5-42 successfully reduced disease markers. Its ability to lower hepatic steatosis and fibrogenesis was comparable to that of the clinical-phase candidate ARO-HSD.
conclusionThis research provides a promising therapeutic candidate and a solid, human-relevant preclinical siRNA testing framework, reducing dependence on animal models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.